'Update on Scheme of Arrangement' that in continuation of our earlier intimations dated March 18, 2026, with…
As filed · Orchid Pharma Limited has informed the Exchange regarding 'Update on Scheme of Arrangement' that in continuation of our earlier intimations dated March 18, 2026, with respect to the merger petition, w
What happened
FactOrchid Pharma Limited has provided an update regarding the Scheme of Amalgamation with Dhanuka Laboratories Limited, which involves the merging of the two companies and their respective shareholders and creditors. The company will submit the copy of the order from the Hon’ble NCLT when it becomes available. Investors are requested to take this intimation on record.
Why it matters
CapitSignal interpretationOnce an insolvency process is admitted, control of the company passes from the board to a resolution professional and equity ranks last in any recovery.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Capex
DelayedWe'll probably have the exact number, say, after a few months' time.
as our cefiderocol project will get started, say, in the next year, then we will take validation batches and hopefully, after two years, we would be able to -- once we are able to register the product from our side, we would be able to supply some percentage from our side.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Admission or rejection of the application by the tribunal
- Appointment of a resolution professional
- Claims admitted against the company
- Hopefully, within this quarter, we should announce one. (management committed by Q4 FY26)
- The first sales actually would be to Orchid itself internally. (management committed by Q1 FY27)
Evidence
How CapitSignal classified this
- Reasoning:
- INSOLVENCY base 93; +5 quantified amount; explicit insolvency/default evidence present; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%